Literature DB >> 30384111

Early life adversity blunts responses to pioglitazone in depressed, overweight adults.

Thalia K Robakis1, Kathleen Watson-Lin2, Tonita E Wroolie2, Alison Myoraku2, Carla Nasca3, Benedetta Bigio3, Bruce McEwen3, Natalie L Rasgon2.   

Abstract

PURPOSE: Early life adversity is associated with both metabolic impairment and depression in adulthood, as well as with poorer responses to antidepressant medications. It is not yet known whether individual differences in sensitivity to antidiabetic medications could also be related to early life adversity. We examined whether a history of early life adversity affected the observed changes in metabolic function and depressive symptoms in a randomized trial of pioglitazone for augmentation of standard treatments for depression.
PURPOSE: Early life adversity is associated with both metabolic impairment and depression in adulthood, as well as with poorer responses to antidepressant medications. It is not yet known whether individual differences in sensitivity to antidiabetic medications could also be related to early life adversity. We examined whether a history of early life adversity affected the observed changes in metabolic function and depressive symptoms in a randomized trial of pioglitazone for augmentation of standard treatments for depression.
FINDINGS: We found that early life adversity significantly impaired the metabolic response to pioglitazone. Effects on depressive symptoms did not reach significance, but nonetheless suggested that pioglitazone could mitigate the depressant effects of childhood adversity, only among those insulin resistant at baseline.
CONCLUSIONS: We conclude that a history of early life adversity may impair the body's ability to respond to insulin sensitizing pharmacotherapy, and furthermore that its contribution to resistant depression may function in part via the generation of an insulin resistant phenotype.
Copyright © 2018 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Neuroendocrinology; Other psychopharmacology; Unipolar depression

Mesh:

Substances:

Year:  2018        PMID: 30384111      PMCID: PMC6309647          DOI: 10.1016/j.eurpsy.2018.09.009

Source DB:  PubMed          Journal:  Eur Psychiatry        ISSN: 0924-9338            Impact factor:   5.361


  26 in total

Review 1.  Pharmacogenomics of oral antidiabetic medications: current data and pharmacoepigenomic perspective.

Authors:  Vangelis G Manolopoulos; Georgia Ragia; Anna Tavridou
Journal:  Pharmacogenomics       Date:  2011-08       Impact factor: 2.533

2.  The effect of pioglitazone and resistance training on body composition in older men and women undergoing hypocaloric weight loss.

Authors:  M Kyla Shea; Barbara J Nicklas; Anthony P Marsh; Denise K Houston; Gary D Miller; Scott Isom; Michael E Miller; J Jeffrey Carr; Mary F Lyles; Tamara B Harris; Stephen B Kritchevsky
Journal:  Obesity (Silver Spring)       Date:  2011-01-13       Impact factor: 5.002

3.  Does pioglitazone improve depression through insulin-sensitization? Results of a randomized double-blind metformin-controlled trial in patients with polycystic ovarian syndrome and comorbid depression.

Authors:  Ladan Kashani; Targol Omidvar; Behnoud Farazmand; Amirhossein Modabbernia; Fatemeh Ramzanzadeh; Ensiyeh Shahrokh Tehraninejad; Mandana Ashrafi; Mina Tabrizi; Shahin Akhondzadeh
Journal:  Psychoneuroendocrinology       Date:  2012-09-19       Impact factor: 4.905

Review 4.  The mechanisms of action of PPARs.

Authors:  Joel Berger; David E Moller
Journal:  Annu Rev Med       Date:  2002       Impact factor: 13.739

5.  Rosiglitazone add-on in treatment of depressed patients with insulin resistance: a pilot study.

Authors:  Natalie L Rasgon; Heather A Kenna; Katherine E Williams; Bevin Powers; Tonita Wroolie; Alan F Schatzberg
Journal:  ScientificWorldJournal       Date:  2010-02-19

Review 6.  Depression and type 2 diabetes: inflammatory mechanisms of a psychoneuroendocrine co-morbidity.

Authors:  Michael J Stuart; Bernhard T Baune
Journal:  Neurosci Biobehav Rev       Date:  2011-10-14       Impact factor: 8.989

7.  Development and validation of a brief screening version of the Childhood Trauma Questionnaire.

Authors:  David P Bernstein; Judith A Stein; Michael D Newcomb; Edward Walker; David Pogge; Taruna Ahluvalia; John Stokes; Leonard Handelsman; Martha Medrano; David Desmond; William Zule
Journal:  Child Abuse Negl       Date:  2003-02

8.  Adverse childhood experiences and the risk of depressive disorders in adulthood.

Authors:  Daniel P Chapman; Charles L Whitfield; Vincent J Felitti; Shanta R Dube; Valerie J Edwards; Robert F Anda
Journal:  J Affect Disord       Date:  2004-10-15       Impact factor: 4.839

9.  Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma.

Authors:  Charles B Nemeroff; Christine M Heim; Michael E Thase; Daniel N Klein; A John Rush; Alan F Schatzberg; Philip T Ninan; James P McCullough; Paul M Weiss; David L Dunner; Barbara O Rothbaum; Susan Kornstein; Gabor Keitner; Martin B Keller
Journal:  Proc Natl Acad Sci U S A       Date:  2003-11-13       Impact factor: 11.205

10.  The antidepressant-like effects of pioglitazone in a chronic mild stress mouse model are associated with PPARγ-mediated alteration of microglial activation phenotypes.

Authors:  Qiuying Zhao; Xiaohui Wu; Shuo Yan; Xiaofang Xie; Yonghua Fan; Jinqiang Zhang; Cheng Peng; Zili You
Journal:  J Neuroinflammation       Date:  2016-10-04       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.